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Background: Oxidative stress is involved in oral lichen planus (OLP) pathogenesis; meanwhile anthocyanins are 
natural antioxidants present in grapes skin.
Objectives: The aim of this research was to verify the utility of anthocyanins, extracted from grapes skin, for 
the local treatment of oral lichen planus and to compare it with clobetasol propionate- neomycin -nystatin cream 
(CP-NN).
Study Design: Prospective, non-randomized study, with control group. Fifty-two patients with OLP were includ-
ed. We divided patients into two categories: erosive oral lichen planus (EOLP) and non erosive oral lichen planus 
(NEOLP). 38 had EOLP (17 cases and 21 controls) and 14 presented NEOLP types (9 cases and 5 controls).Cases 
received local treatment with anthocyanins from grapes and controls, were treated with CP-NN. The clinical evo-
lution of patients was followed up during six months.
Results: The patients had a therapeutic response with anthocyanins. This was better than CP-NN treatment for 
patients with EOLP, in improving the involvement score of the oral mucosa and in the morphometric study of 
the affected areas. In EOLP there were no statistically significant differences in: therapeutic response time, the 
evolution of pain, or the relapse rate between the two groups. With respect to the treatment of NEOLP there was 
improved pain relief in the group treated with anthocyanins. This was not observed with CP-NN. The resting 
analized variables showed no significant difference with both treatments. 
Conclusions: OLP has a favorable response to local treatment with anthocyanins from grapes. We found an equal 
to or better response than with CP-NN treatment. Many of our patients have systemic diseases, which may con-
traindicate the use of steroids. With regard to this particular group, the use of this natural antioxidant present in 
the diet is considered advantageous.
Key words: Anthocyanins, antioxidants, chemoprevention, morphometry, oral lichen, oxidative stress. 
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Introduction
OLP is a chronic disease of unknown etiology and 
autoimmune pathogenesis. The presence of oxidative 
stress in OLP has been demostrated. It is caused by an 
imbalance between the production of reactive oxygen 
species (ROS); and the ability of tissues to neutralize 
the reactive intermediates or repair the resulting damage 
(1). The formation of lesions with potentially mutagenic 
DNA due to oxidative stress, related to inflammation, 
may contribute to the development of oral cancer in OLP 
(2,3). It occurs in atrophic, bullous and erosive OLP, but 
not usually in reticular clinical forms. Based on these 
pathophysiological observations, we decided to perform 
a therapeutic experience with topical antioxidants in pa-
tients with OLP. The extracts of grape seeds and grape 
skins contain anthocyanins (from greek anthos: flower 
and kyanos: blue) (4). Anthocyanins are considered “the 
main antioxidants of the plant kingdom” as they block 
the spread of free radicals (5). These are polyphenolic 
groups which are present also in other fruits, vegeta-
bles, chocolate, tea, among others. An average person 
consumes 180-1000 mg. / day of these substances (6).
Material and Methods
The present study was approved by the Ethic Commit-
tee of the Lagomaggiore Hospital of Mendoza, Argen-
tina. Written informed consent was obtained from each 
subject. Fifty two patients with all clinical types of OLP 
were included in this study. To achieve a more accurate 
comparison, patients were subdivided into EOLP and 
NEOLP forms. In the group EOLP erosive and bullous 
forms were included. NEOLP comprised reticular, kera-
totic, pigmentary and atrophic OLP forms. Biopsy was 
performed on 45 patients. In two of them results were 
nonspecific and the rest confirmed diagnosis. 
Inclusion and exclusion criteria: patients with clinical 
manifestations of OLP were included in this study. Pa-
tients younger than 16 years old and patients with ante-
cedents of organ transplants were excluded. 
Study design: Prospective, non-randomized study, with 
control group. All patients of this study received treat-
ment for dental septic foci and were educated in teeth 
brushing techniques. We divided patients into two cat-
egories: EOLP and NEOLP clinical forms. These cat-
egories were then divided into two groups each one: 
cases, with local treatment with anthocyanins from 
grapes, and controls, treated with CP-NN. The clinical 
evolution of patients was followed up over six months. 
For the cases group we indicated natural red colorant 
0352 Christian Hansen Laboratories Argentina. This is 
used as a colorant in the food industry. It is a violet-
colored powder. Its ingredient is purified anthocyanin 
from grapes, Vitis vinifera. Anthocyanins were ad-
ministered in 100 mg./doses diluted in 5 ml of water, 
mouth rinses, during 5 minutes and spit, three times a 
day. This amount, is lower than the average dose usually 
ingested (6,7). Furthermore this quantity was compared 
in vitro with the equivalent of 225 mg of vitamin E, 
and showed higher scavenger effect on ROS (8,9). The 
control group received: CP-NN cream (100 g of com-
mercial preparation containing: 17-clobetasol propion-
ate (micronized) 0.050 g, Neomycin (as sulfate) 0.350 g; 
Nystatin (micronized) 100.000 U / g. This was applied 
three times daily locally on lesions. The follow up was 
protocolized and there were considered among other 
parameters: epidemiological data, presence of systemic 
diseases and treatments, degree of pain, graded from 0 
to 10 and measured through verbal analogue scale, days 
to achieve improvement, relapse, measurement of the 
involved areas and dental indices. We performed a total 
compromise score dividing mouth into 14 sectors and 
evaluating each one as: Normal= 1, moderate injury= 2 
and serious injury= 3 (Table 1). A morphometric study 
of the lesions was performed. Image Pro Plus (software 
and image analyzer processor) was used to examine the 
images obtained during examinations. Affected areas 
were compared at the initial and improvement consulta-
tions in cases and controls.
Epidemiological data were analyzed using Epi-info. 
This included an analysis of central tendency and dis-
persion measures, Student’s t test and Fisher exact test. 
The morphometric analysis was analyzed with Graph-
Pad InStat 3.0 and GraphPad Prism version 5. We used 
Fisher’s exact test, Wilcoxon test, Mann-Whitney, 
ANOVA, Kruskal-Wallis and Friedman test as appro-
priate. A value of p ≤ 0.05 was considered significant.
Results
Fifty-two patients with OLP were included. 38 had EOLP 
(17 cases and 21 controls) and 14 presented NEOLP types 
(9 cases and 5 controls). The average age was 61.6 years 
(SD ± 10.6), 87.5% were women. In 77.1% of them (95% 
CI 62.69 to 87.97) the evolution of OLP was over one 
year. 87.5% (95% CI 74.75 to 95.27) had also other dis-
eases. 71% of patients ingested three or more drugs, The 
main drugs included antihypertensives (inhibitors of an-
giotensin converting enzyme, beta blockers and calcium 
channel blockers), thyroid hormones and antidepressants 
among others. 53.85% had amalgam restorations, and in 
two patients a history of B hepatitis was found. Caries 
accounted for 50% of cases and 48% of controls. 60% 
and 78% of patients used dentures in respective group. 
Plaque was present in 76% of cases and 83% of controls 
and calculus were 68% and 52% respectively.
There was no significant difference between patients 
who had amalgams and those without them (p= 0.36), 
neither between EOLP and NEOLP forms (p= 0.32) at 
baseline. The difference between means, in the number 
of days to reach improvement, was not statistically 
significant (p= 0.63), neither in patients undergoing 








Saliva      Aqueous             Thick              Absent
Border Soft pink and wet Dry or fissured Ulcer or bleeding
Superior lip Soft pink and wet Indentations or erythema Ulcer or bleeding
Inferior lip Soft pink and wet Indentations or erythema Ulcer or bleeding
Dorsum  tongue Pink wet and papillae present Saburra or erythema. Mycosis Blisters or fissure
Ventral tongue Pink and wet Red or cover without ulcerations. 
Mycosis
Ulceration
Right border of the 
tongue
Pink and wet Red or cover without ulcerations. 
Mycosis
Ulceration
Left border of the 
tongue
Pink and wet Red or cover without ulcerations. 
Mycosis
Ulceration
Right buccal muccosa Pink and wet Red or cover without ulcerations. 
Mycosis
Ulceration
Left buccal muccosa Pink and wet Red or cover without ulcerations. 
Mycosis
Ulceration
Palate Pink and wet Red or cover without ulcerations. 
Mycosis
Ulceration
Floor of the mouth Pink and wet Red or cover without ulcerations. 
Mycosis
Ulceration
Gums Pink and firm Edematous with or without 
erythema , soft
Bleeding
Teeth Clean and without calculus Plaque or calculus in localized 
areas (between teeth)
Generalized dental plaque 
or calculus
SCORE
Table 1. Total compromise score. Mouth is divided into 14 sectors or categories and each one is evaluated as: Normal= 1, moderate injury= 
2 and serious injury= 3.
removal of amalgams or those who remained with the 
same restorations (p= 0.18).
Oral compromise scores in patients with EOLP exhi-
bited no significant difference initially between groups 
(p= 0.79). The difference of initial scores, paired with 
the visit of improvement was significant (p= 0.01) in 
cases group.There was also a significant difference seen 
with ANOVA when lesions were evaluated at the ini-
tial consultation and three subsequent controls (Fig. 1) 
(p= 0.0039). In the control group with EOLP the scores 
compared between initiation and improvement, showed 
significant difference (paired t test, p = 0.0008) also. 
This difference was not demonstrated in the follow up 
scores (Fig. 1) (ANOVA, p= 0.27). In patients with NE-
OLP scores of initial control matched with the improve-
ment visit (paired t test), showed no significant differ-
ence for cases (p= 0.99) neither for controls (p= 0.62). 
In these patients with NEOLP no significant differences 
were seen with ANOVA comparing the initial and sub-
sequent consultations; in both groups: cases (p= 0.71) 
and controls (p= 0.06). 
In patients with EOLP and NEOLP forms we found no 
significant difference in the degree of pain at baseline 
between the groups. Matched analysis of pain at the first 
visit and at the time of improvement showed significant 
difference in cases (p= 0.0001) and in controls (p= 
0.0007). The comparison showed no significant diffe-
rences neither in the improvement of the degree of pain 
nor in the time to improve with both treatments. In pa-
tients with NEOLP lichen, the cases group demonstrat-
ed significant difference (p= 0,03) comparing the initial 
and the improvement control. In the control group, there 
was no significant difference (p= 0.24) between base-
line and the recovery consultation. 
The final consultation was performed on 27 patients with 
EOLP lichen. The group included 14 cases and 13 con-
trols.It was seen that the response was good in 12 of 14 
(85%) in the cases group and in 9 of 13 (69%) of the con-
trol group (p= 0.64) The response was poor in 14% of the 
case group and 23% in the control group (p=0.38). The 
mean treatment time was 164 days (DS±70.8) in the case 
group and 145.7 (DS±77.9) in the controls. No significant 
differences were seen between both groups (p= 0.53).
In patients with NEOLP there was no significant dif-
ference in the number of days since the first consul-
tation to final inspection, neither in the lesions and 
symptoms improvement (p= 1.00) comparing both 
treatments.
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Fig. 1. Evolution of scores in patients with EOLP with both treatments. In patients treated with anthocyanins there was significant difference 
when lesions were evaluated at the initial consultation and three subsequent visits. In the control group this difference was not demonstrated in 
the follow up scores.
Fig. 2. Morphometric study. Affected areas at baseline versus the affected areas in the clinical assessment of improvement, in a patient, with 
EOLP treated with anthocyanins. A: date: 18-12-06 and B: evolution: 16-01-07.
Morphometric study: The comparison of the affected 
areas at baseline did not show significant difference nei-
ther in EOLP (p= 0.49) nor in NEOLP (p= 0.31). In the 
EOLP cases group, analyzing the affected areas at base-
line versus the affected areas in the clinical assessment 
of improvement (Fig. 2, Table 2), with the Wilcoxon test 
for paired samples, we encountered p <0.0003, consid-
ered extremely significant. In EOLP control group (Ta-
ble 2): we found p = 0.0035, considered very significant. 
In EOLP comparing the percentages of improvement in 
the measured areas, it was greater for the case group 
(p=0.02) (Fig. 3). In patients with NEOLP (Table 3) 
with Student’s t test for paired samples, we did not find 
significant difference in the areas affected at the begin-
ning and end of treatment in NEOLP cases(p= 0.13) and 
in controls (p= 0.30).
Time to reach the improvement: (Table 2) for patients 
in EOLP case group the average to achieve improve-
ment was 49 days (SD ± 64.39). In the control group 
mean to achieve the improvement was 45 days (36.10 
± DS).There was no significant difference between the 
two groups (p= 0.82). Regarding NEOLP (Table 3) no 
significant differences were found between groups for 
reaching improvement either (p=0.38). 
Discussion
This work was designed and aimed at treating OLP with 
anthocyanins, a natural antioxidant substance that si-
multaneously has proven to have no toxic effects.
In our patients, the most frequent concomitant diseases 
were hypertension, depression, diabetes and hypothy-
roidism. To date, local corticosteroids are of choice, but 
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Table 2. EOLP. Measured areas and days to improvement.







DAYS TO                 
IMPROVE 
1 f 75 1,7679654 0,1696849 90,40% 29 
2 f 64 0,1419381 0 100% 14 
3 f 56 2,9071125 0,5917384 79,65% 28 
4 f 69 16,84899 4,256694 74,74% 72 
5 f 62 3,855381 0 100% 14 
7 f 61 8,48934 1,098746 87,06% 270 
9 f 69 1,8137412 0,3939587 78,28% 34 
10 m 57 0,2561452 0,0198277 92,26% 13 
12 f 59 1,1225 0,1271779 88,67% 10 
13 f 49 26,69657 12,45422 53,35% 30 
14 f 47 3,685324 0,9290665 74,79% 41 
25 f 42 7,862044 1,232135 84,33% 19 
16 f 67 0,2027559 0,091792 54,73% 59 
17 f 62 0,4868276 0,349132 28,28% 134 
18 f 75 2,693908 0 100% 31 
19 f 68 1,927768 0,0530158 97,25% 28 
22 f 63 2,221976 0,2705205 87,83% 14 
       









1 m 65 1,027277 0,1621009 84,22% 37 
2 f 62 12,57216 3,813805 69,66% 72 
3 m 77 0,6828904 0,3648334 46,58% 25 
4 f 40 0,3108621 0,5576809 -79,40% 12 
5 f 78 0,1724597 0 100% 25 
6 f 68 0,1577957 0 100% 110 
7 f 62 12,73963 1,617654 87,30% 14 
8 f 68 0,2008812 0,1296833 35,44% 49 
9 f 55 15,27682 15,95812 -4,46% 14 
10 f 73 6,665225 0 100% 14 
11 m 81 0,4559819 0,0212103 95,35% 24 
12 f 63 11,25934 10,340531 8,16% 14 
13 f 75 2,523462 0,8117248 67,83% 17 
14 f 46 2,22264 3,569924 -60,62% 111 
15 m 57 0,9870581 0,2821496 71,42% 35 
16 f 54 1,346657 1,30708 2,94% 59 
17 f 64 8,0009028 1,2386076 84,52% 14 
18 f 60 2,854775 1,087392 61,91% 126 
19 f 52 0,5137617 0,3113988 39,39% 83 
20 f 85 1,564966 0,9837283 37,14% 37 
21 f 56 1,2993205 0,4283993 67,03% 65 
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Table 3. NEOLP. Measured areas and days to improvement.
Fig. 3. Percentages of improvement in EOLP. In patients with EOLP comparing the percentages of 
improvement in the measured areas, it was greater for the case group (p=0.02).






DAYS TO IMPROVE 
1 f 72 17,29119 1,420237 91,79% 129 
2 f 48 1,7273565 0,7899807 54,27% 29 
3 f 73 5,056685 3,099983 38,70% 28 
4 f 51 0,3293575 0,2920802 11,32% 21 
5 f 52 1,3732073 0,4361917 68,24% 27 
6 m 56 1,57579 0,62035 60,63% 37 
7 f 41 0,6413303 0,3911531 39,01% 450 
7 f 65 4,960471 1,868476 62,33% 98 
9 f 76 2,64782 1,476103 44,25% 23 
      






DAYS TO IMPROVE 
1 f 74 26,101435 1,22501 95,31% 45 
2 f 66 1,938971 0,9755708 49,69% 42 
3 m 54 6,213268 0,1039345 98,33% 45 
4 f 64 2,197988 7,275645 -231,01% 35 
5 f 53 10,09516 7,145246 29,22% 17 
absorption through the mucosa has been demonstrated 
causing inhibition of the hypothalamic pituitary adrenal 
axis (10). Corticosteroid systemic effects are known to 
increase blood pressure, induce psychosis and elevate 
blood glucose levels among others. Another medica-
tion, with the same local therapeutic effects of corti-
costeroids would be very usefull specially if it does not 
damage the health of patients. In relation to the known 
treatments and oral cancer, tacrolimus has been related 
to carcinogenic potential and this leads us to reconsid-
er the benefits of its application, particularly because 
OLP has malignant potential especially in erosive and 
atrophic forms (11).
Anthocyanins modulate apoptosis and signals that 
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provide links between inflammation and cancer, and 
further regulate tumor angiogenesis and invasiveness 
(12). Numerous reports demonstrate anthocyanins high 
bioavailability and their protection against diseases in-
duced by free radicals such aging and carcinogenesis 
(13-15). In our clinical research, we demonstrated the 
usefulness of anthocyanins therapy for the treatment of 
OLP, especially in erosive forms, which are known to 
be potentially malignizables.
Caries, dentures, dental plaque and calculus, are den-
tal condition present in our patients and they are not 
favorable for the use of local corticosteroids due to its 
immunosuppressive effect. Grapes polyphenols inhibit 
growth of Escherichia coli. Staphylococcus aureus, and 
Candida albicans (16). So the anti-inflammatory effect 
of anthocyanins could add antibacterial and antifungal 
properties (17,18). Similarly, those effects were added to 
the control group through neomycin and nystatin.
When evaluating compromise scores along the follow 
up, we found that patients with EOLP, cases and con-
trols, improved their scores significantly in both groups. 
There was no statistical difference in the number of 
days until the scores improved. On subsequent visits, 
it was recorded that in those treated with anthocyanins 
improvement continued increasing and there were sig-
nificant differences when analyzing the first and the 
three following queries. Meanwhile we could not dem-
onstrate significant differences in the control group 
between the first consultation and the three later. We 
consider this find of great importance because it shows 
statistically significant, better therapeutic results with 
anthocyanins. It is considered to occur in EOLP, which 
are already known to be potentially malignizables, and 
corticosteroids can have even an immunosuppressive 
effect in these patients. In patients with NEOLP no 
significant differences were found along the follow up 
with the both treatments. It is relevant to have found that 
treatment with anthocyanins has been found to have the 
same effect as realized with the CP-NN, which is the 
highest potency corticosteroid known and is the gold 
standard local treatment.
Conclusions: OLP has a favorable response to local 
treatment with anthocyanins from grapes. In patients 
with EOLP an equal to better response than with CP-
NN treatment was noted.
The presence of amalgams did not influence the clini-
cal course of our patients. The compromise scores 
showed that EOLP patients progressively improved 
with anthocyanins along the course of follow up. In 
NEOLP patients there was no significant difference. 
Regarding the pain, although there is a tendency to a 
better response with anthocyanins, in EOLP there was 
no significant difference between groups. In NEOLP 
patients the response of pain was significantly better 
with anthocyanins. We found no significant difference 
between groups in the time to reach improvement and 
the percentage of relapses. In the morphometric analy-
sis of patients with EOLP the percentage of improve-
ment was higher for the group cases. In patients with 
NEOLP no differences between treatments were found 
There were no side effects related to local treatments 
performed during this work. Many of our patients have 
other diseases, which may contraindicate the use of 
steroids. Especially in these persons, it is considered to 
be an advantage in the use of this natural antioxidant 
present in grapes. There is extensive literature linking 
anthocyanins with chemoprophylaxis of diseases relat-
ed to oxidative stress. New contributions are necessary 
to consider the effect of anthocyanins in other oral in-
flammatory conditions, especially in those with chronic 
course or malignant potential, where oxidative stress 
plays a role in the pathogenesis.
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